Figure 6. In vivo efficacy of olaparib in combination with FK866 inhibitor in TN breast cancer xenografts.

CAL51 cells were xenografted into immunocompromised mice and once xenografts had established, mice were treated as described in the Materials and Methods section.

1. The therapeutic effect of each therapy compared to vehicle-treated mice is shown for olaparib alone, FK866 alone and the olaparib/FK866 combination. Each data point represents the mean increase in tumour volume after the instigation of treatment and error bars represent SEM, where n for each cohort = 10 animals; *p < 0.05 (repeated measures ANOVA with post-test) comparing the FK866/olaparib combination arm versus each other cohort, refer to Supporting Information Table S5 for statistical analysis.
2. Body weight in each cohort.